Gilles Robinet

TL;DR: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations as discussed by the authors.

TL;DR: First-line durvalumab plus platinum-etoposide significantly improved overall survival in patients with ES-SCLC versus a clinically relevant control group and safety findings were consistent with the known safety profiles of all drugs received.

TL;DR: Clinical important differences in the median, 2, 3, and 4-year survival rates were observed, with a trend in favor of concurrent chemoradiation therapy, suggesting that is the optimal strategy for patients with locally advanced NSCLC.

TL;DR: Onartuzumab plus erlotinib was associated with improved PFS and OS in the MET-positive population, and these results combined with the worse outcomes observed in MET-negative patients treated with onartuzuab highlight the importance of diagnostic testing in drug development.

TL;DR: Treatment with durvalumab resulted in a numerically reduced risk of death vs chemotherapy in patients with programmed cell death ligand 1 expression on at least 25% of tumor cells, highlighting the need for further investigation and prospective validation of blood tumor mutational burden as a predictive biomarker for immunotherapy.